Oldwick, New Jersey-based Provention Bio’s PRV-6527, which was licensed from Johnson & Johnson company Janssen, failed in a mid-stage clinical trial.

Japan’s Takeda Pharmaceutical presented more data from the company’s Phase IIIb head-to-head VARSITY clinical trial of Entyvio compared to AbbVie’s Humira in ulcerative colitis.

RedHill Biopharma reported positive safety and efficacy results from a late-stage clinical trial for the Israeli company’s treatment for Crohn’s disease called RHB-104.

Janssen Pharmaceutical of Johnson & Johnson inked a global collaboration deal with Theravance Biopharma to develop a drug for inflammatory bowel diseases (IBD).

Takeda Pharmaceutical Company Limited and Portal Instruments announced a collaboration to develop and commercialize Portal’s needle-free drug delivery device for potential use with Takeda’s investigational or approved biologic medicines.

J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.

Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.

With the 2015 record-breaking biopharma merger-and-acquisition period about to come to an end, analysts are tuning their crystal balls to 2016. So far this year—not quite done yet—there has been $667.5 billion in healthcare mergers and acquisitions, according to Dealogic. Next year is likely to continue a trend that started, or at least accelerated, last […]

AstraZeneca enters into agreement with Perrigo for rights to Entocort in the US Divestment  further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015   23 November 2015 AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights […]

Johnson & Johnson’s Stelara was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat the skin condition […]